Shares of Horizon Discovery (LON:HZD) have been given a consensus rating of “Buy” by the seven analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is GBX 225 ($3.05).
A number of analysts recently commented on HZD shares. Numis Securities restated a “buy” rating and set a GBX 300 ($4.07) price target on shares of Horizon Discovery in a research note on Tuesday, March 6th. N+1 Singer lowered their target price on shares of Horizon Discovery from GBX 250 ($3.39) to GBX 230 ($3.12) and set a “buy” rating on the stock in a research note on Monday, February 19th. Finally, Peel Hunt reiterated a “hold” rating on shares of Horizon Discovery in a research note on Thursday, May 10th.
In other news, insider Jonathan Milner bought 370,000 shares of the stock in a transaction on Thursday, April 5th. The shares were acquired at an average cost of GBX 132 ($1.79) per share, for a total transaction of £488,400 ($662,506.78).
Shares of HZD stock opened at GBX 182 ($2.47) on Wednesday. Horizon Discovery has a 12 month low of GBX 160 ($2.17) and a 12 month high of GBX 294 ($3.99).
About Horizon Discovery
Horizon Discovery Group plc, a life science company, engages in precision gene editing to design, build, and apply cells to advance human health worldwide. Its core capabilities are built around its proprietary transnational genomics platform, a suite of gene editing tools, such as rAAV, ZFN, and CRISPR to alter gene sequence in human or mammalian cell-lines.
Receive News & Ratings for Horizon Discovery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery and related companies with MarketBeat.com's FREE daily email newsletter.